Pharmacokinetics of selective serotonin reuptake inhibitors

Pharmacology and Therapeutics

Volumn 85, Issue 1, 2000, Pages 11-28

  Hiemke, Christoph ^a   Härtter, Sebastian ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Citalopram; Drug drug interactions; Fluoxetine; Fluvoxamine; Paroxetine; Sertraline

Indexed keywords

CITALOPRAM; CYTOCHROME P450; FLUOXETINE; FLUVOXAMINE; NORFLUOXETINE; PAROXETINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

DEPRESSION; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INTERACTION; DRUG METABOLISM; HUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW; SEROTONINERGIC SYSTEM;

CITALOPRAM; CLINICAL TRIALS; DRUG INTERACTIONS; FLUOXETINE; FLUVOXAMINE; HUMANS; PAROXETINE; SEROTONIN UPTAKE INHIBITORS; SERTRALINE;

EID: 0344110152     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(99)00048-0     Document Type: Review

References (205)

1. Albers L.A., Reist C., Helmeste D., Vu R., Tang S.W. Paroxetine shifts imipramine metabolism. Psychiatry Res. 59:1996;189-196.
2. Alderman J., Preskorn S.H., Greenblatt D.J., Harrison W., Penenberg D., Allison J., Chung M. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol. 17:1997;284-291.
3. Amsterdam J.D., Fawcett J., Quitkin F.M., Reimherr F.W., Rosenbaum J.F., Michelson D., Hornig-Rohan M., Beasley C.M. Fluoxetine and norfluoxetine plasma concentrations in major depression. a multicenter study Am J Psychiatry. 154:1997;963-969.
4. Apseloff G., Wilner K.D., Gerber N., Tremaine L.M. Effect of sertraline on protein binding of warfarin. Clin Pharmacokinet. 32(suppl. 1):1997;37-42.
5. Aranow R.B., Hudson J.I., Pope H.G. Jr., Grady T.A., Laage T.A., Bell I.R., Cole J.O. Elevated antidepressant plasma levels after addition of fluoxetine. Am J Psychiatry. 146:1989;911-913.
6. Avenoso A., Spina E., Campo G., Facciola G., Ferlito M., Zuccaro P., Perucca E., Caputi A.P. Interaction between fluoxetine and haloperidol. pharmacokinetic and clinical implications Pharmacol Res. 35:1997;335-339.
7. Baettig D., Bondolfi G., Montaldi S., Amey M., Baumann P. Tricyclic antidepressant plasma levels after augmentation with citalopram. a case study Eur J Clin Pharmacol. 44:1993;403-405.
8. Barr L.C., Goodman W.K., Price L.H. Physical symptoms associated with paroxetine discontinuation. Am J Psychiatry. 151:1994;289.
9. Baumann P. Pharmacology and pharmacokinetics of citalopram and other SSRIs. Int Clin Psychopharmacol. 11(suppl. 1):1996;5-11. a.
10. Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 31:1996;444-469. b.
11. Baumann P., Larsen F. The pharmacokinetics of citalopram. Rev Contemp Pharmacother. 6:1995;287-295.
12. Baumann P., Rochat B. Comparative pharmacokinetics of selective serotonin reuptake inhibitors. a look behind the mirror Int Clin Psychopharmacol. 10(suppl. 1):1995;15-21.
13. Bayer A.J., Roberts N.A., Allen E.A., Horan M., Routledge P.A., Swift C.G., Byrne M.M., Clarkson A., Zussman B.D. The pharmacokinetics of paroxetine in the elderly. Acta Psychiatr Scand. 80(suppl. 350):1989;85-86.
14. Beasley C.M. Jr., Bosomworth J.C., Wernicke J.F. Fluoxetine. relationships among dose, response adverse events, and plasma concentrations in the treatment of depression Psychopharmacology. 26:1990;18-24.
15. Bech P. A review of the antidepressant properties of serotonin reuptake inhibitors. Adv Biol Psychiatry. 17:1988;58-69.
16. Becquemont L., Le Bot M.A., Riche C., Beaune P. Influence of fluvoxamine on tacrine metabolism in vitro. potential implication for the hepatotoxicity in vivo Fundam Clin Pharmacol. 10:1996;156-157.
17. Bender S., Eap C.B. Very high cytochrome P4501A2 activity and nonresponse to clozapine. Arch Gen Psychiatry. 55:1998;1048-1050.
18. Benfield P., Ward A. Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs. 32:1986;313-334.
19. Benfield P., Heel R.C., Lewis S.P. Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs. 32:1986;481-508.
20. Bengtsson F., Lundmark J., Nordin C., Reis M., Wålinder J. TDM of selective serotonin reuptake inhibitors treating depression in the elderly reduces drug doses and costs. Ther Drug Monit. 19:1997;579.
21. Benkert O., Szegedi A., Wetzel H., Staab H.J., Meister W., Philipp M. Dose escalation vs. continued doses of paroxetine and maprotiline. a prospective study in depressed out-patients with inadequate treatment response Acta Psychiatr Scand. 95:1997;288-296.
22. Bergstrom R.F., Peyton A.L., Lemberger L. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther. 51:1992;239-248.
23. Bertschy G., Vandel S., Vandel B., Allers G., Volmat R. Fluvoxamine-tricyclic antidepressant interaction. Eur J Clin Pharmacol. 40:1991;119-120.
24. Bertschy G., Baumann P., Eap C.B., Baettig D. Probable metabolic interaction between methadone and fluvoxamine in addict patients. Ther Drug Monit. 16:1994;42-45.
25. Bjerkenstedt L., Flyckt L., Fredricson-Overø K., Lingjærde O. Relationship between clinical effects, serum drug concentration and serotonin uptake inhibition in depressed patients treated with citalopram. Eur J Clin Pharmacol. 28:1985;553-557.
26. Bloomer J.D.C., Woods F.R., Haddock R.E., Lennard M.S., Tucker G.T. The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. Br J Clin Pharmacol. 33:1992;521-523.
27. Breyer-Pfaff U., Pfandl B., Nill K., Nusser E., Monney C., Jonzier-Perey M., Baettig D., Baumann P. Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes. Clin Pharmacol Ther. 52:1992;350-358.
28. Brøsen K. Are pharmacokinetic drug interactions with the SSRIs an issue? Int Clin Psychopharmacol. 11(suppl. 1):1996;23-27.
29. Brøsen K., Gram L.F. First-pass metabolism of imipramine and desipramine. impact of the sparteine oxidation phenotype Clin Pharmacol Ther. 43:1988;400-406.
30. Brøsen K., Skjelbo E. Fluoxetine and norfluoxetine are potent inhibitors of P450IID6 - the source of the sparteine/debrisoquine oxidation polymorphism. Br J Clin Pharmacol. 32:1991;136-137.
31. Brøsen K., Skjelbo E., Rasmussen B.B., Pousen H.E., Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol. 45:1993;1211-1214.
32. Caccia S., Cappi M., Fracasso C., Garattini S. Influence of dose and route of administration on the kinetics of fluoxetine and its metabolite norfluoxetine in the rat. Psychopharmacology. 100:1990;509-514.
33. Carrillo J.A., Dahl M.L., Svensson J.O., Alm C., Rodriguez I., Bertilsson L. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clin Pharmacol Ther. 60:1996;183-190.
34. Catterson M.L., Preskorn S.H. Pharmacokinetics of selective serotonin reuptake inhibitors. clinical relevance Pharmacol Toxicol. 78:1996;203-208.
35. Centorrino F., Baldessarini R.J., Frankenburg F.R., Kando J., Volpicelli S.A., Flood J.G. Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am J Psychiatry. 153:1996;820-822.
36. Ching M.S., Blake C.L., Ghabrial H., Ellis S.W., Lennard M.S., Tucker G.T., Smallwood R.A. Potent inhibition of yeast-expressed CYP2D6 by dihydroquinidine, quinidine, and its metabolites. Biochem Pharmacol. 50:1995;833-837.
37. Chong S.A., Tan C.H., Lee H.S. Worsening of psychosis with clozapine and selective serotonin reuptake inhibitor combination. two case reports J Clin Psychopharmacol. 17:1997;68-69.
38. Claassen V. Review of the animal pharmacology and pharmacokinetics of fluvoxamine. Br J Clin Pharmacol. 15:1983;349S-355S.
39. Cole J.O. New directions in antidepressant therapy. a review of sertraline, a unique serotonin reuptake inhibitor J Clin Psychiatry. 53:1992;333-340.
40. Crewe H.K., Lennard M.S., Tucker G.T., Woods F.R., Haddock R.E. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol. 34:1992;262-265.
41. Cusack B., Nelson A., Richelson E. Binding of antidepressants to human brain receptors. focus on never generation compounds Psychopharmacology. 114:1994;559-565.
42. Dalhoff K., Almdal T.P., Bjerrum K., Keiding S., Mengel H., Lund J. Pharmacokinetics of paroxetine in patients with cirrhosis. Eur J Clin Pharmacol. 41:1991;351-354.
43. Daniel D.G., Randolph C., Jaskiw G., Handel S., Williams T., Abi-Dargham A., Shoaf S., Egan M., Elkashef A., Liboff S., Linnoila M. Coadministration of fluvoxamine increases serum concentrations of haloperidol. J Clin Psychopharmacol. 14:1994;340-343.
44. Daniel W.A., Wójcikowski J. Contribution of lyosomal trapping to the total tissue uptake of psychotropic drugs. Pharmacol Toxicol. 80:1997;62-68. a.
45. Daniel W.A., Wójcikowski J. Interactions between promazine and antidepressants at the level of cellular distribution. Pharmacol Toxicol. 81:1997;259-264. b.
46. Paroxetine. a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study J Affect Disord. 18:1990;289-299.
47. Darley J. Interaction between phenytoin and fluoxetine. Seizure. 3:1994;151-152.
48. De Bree H., van der Schoot J.B., Post L.C. Fluvoxamine maleate; disposition in man. Eur J Drug Metab Pharmacokinet. 3:1983;175-179.
49. Dechant K. Paroxetine. a review Drugs. 41:1991;226-253.
50. De Jonghe F., Swinkels J.A. The safety of antidepressants. Drugs. 43(suppl. 2):1992;40-47.
51. den Boer J.A., Westenberm H.G., De Leeuw A.S., van Vliet I.M. Biological dissection of anxiety disorders. the clinical role of selective serotonin reuptake inhibitors with particular reference to fluvoxamine Int Clin Psychopharmacol. 9(suppl. 4):1995;47-52.
52. DeVane C.L., Gill H.S. Clinical pharmacokinetics of fluvoxamine. applications to dosage regimen design J Clin Psychiatry. 58(suppl. 5):1997;7-14.
53. de Vries M.H., Raghoebar M., Mathlener I.S., van Harten J. Single and multiple oral dose fluvoxamine kinetics in young and elderly subjects. Ther Drug Monit. 14:1992;493-498.
54. de Vries M.H., van Harten J., van Bemmel P., Raghoebar M. Pharmacokinetics of fluvoxamine maleate after increasing single oral doses in healthy subjects. Biopharm Drug Dispos. 14:1993;291-296.
55. De Wilde J.E.M., Doogan D.P. Fluvoxamine and chlorimipramine in endogenous depression. J Affect Disord. 4:1982;249-259.
56. Dominguez R.A., Kumar A.M., Cua W. Lack of change in fluoxetine and norfluoxetine kinetics when switching from fluoxetine to paroxetine. J Clin Psychopharmacol. 16:1996;320-323.
57. Doyle G.D., Laher M., Kelly J.G., Byrne M.M., Clarkson A., Zussman B.D. The pharmacokinetics of paroxetine in renal impairment. Acta Psychiatr Scand. 80(suppl. 350):1989;89-90.
58. Ereshefsky L., Riesenman C.L., Lam Y.W.F., Simpson J. CYP2D6 drug interaction potential of four SSRI's using in vivo dextromethorphan. Eur Neuropsychopharmacol. 6(suppl. 3):1996;42.
59. Fjordside L., Jeppesen U., Eap C.B., Powell K., Baumann P., Brøsen K. The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine. Pharmacogenetics. 9:1999;55-60.
60. Fleishaker J.C., Hulst L.K. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol. 46:1994;35-39.
61. Foglia J.P., Pollock B.G., Kirshner M.A., Rosen J., Sweet R., Mulsant B. Plasma levels of citalopram enantiomers and metabolites in elderly patients. Psychopharmacol Bull. 33:1997;109-112.
62. Frazer A. Pharmacology of antidepressants. J Clin Psychopharmacol. 17(suppl. 2):1997;2S-18S.
63. Fredricson-Overø K. Kinetics of citalopram in man; plasma levels in patients. Prog Neuropsychopharmacol Biol Psychiatry. 6:1982;311-318.
64. Fredricson-Overø, K. (1987). The role of pharmacokinetics in the development of new drugs: an illustration by studies on citalopram. Thesis, University of Copenhagen.
65. Fredricson-Overø K., Toft B., Christophersen L., Gylding-Sabroe J.P. Kinetics of citalopram in elderly patients. Psychopharmacology. 86:1985;253-257.
66. Fuller R.W., Perry K.W., Molloy B.B. Effect of 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine on the depletion of brain serotonin by 4-chloroamphetamine. J Pharmacol Exp Ther. 193:1975;796-803.
67. Fuller R.W., Snoddy H.D., Krushinski J.H., Robertson D.W. Comparison of norfluoxetine enantiomers as serotonin uptake inhibitors in vivo. Neuropharmacology. 31:1992;997-1000.
68. George J., Byth K., Farrell G.C. Age but not gender selective affects expression of individual cytochrome P450 proteins in human liver. Biochem Pharmacol. 50:1995;727-730.
69. Gonzales F.J. Human cytochromes P450. problems and prospects Trends Pharmacol Sci. 13:1992;346-352.
70. Goodnick P.J., Goldstein B.J. Selective serotonin reuptake inhibitors in affective disorders-I. Basic pharmacology. J Psychopharmacol. 12(3 suppl. B):1998;S5-S20.
71. Gram L.F. Fluoxetine. N Engl J Med. 331:1994;1354-1361.
72. Gram L.F., Hansen M.G.J., Sindrup S.H., Brøsen K., Poulsen J.H., Aaes-Jørgensen T., Overø K.F. Citalopram. interaction studies with levomepromazine, imipramine and lithium Ther Drug Monit. 15:1993;18-24.
73. Greenblatt D.J., Preskorn S.H., Cotreau M.M., Horst W.D., Harmatz J.S. Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther. 52:1992;479-486.
74. Greenblatt D.J., von Moltke L.L., Schmider J., Harmatz J.S., Shader R.I. Inhibition of human cytochrome P450-3A isoforms by fluoxetine and norfluoxetine. in vitro and in vivo studies J Clin Pharmacol. 36:1996;792-798.
75. Gunasekara N.S., Noble S., Benfield P. Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders. Drugs. 55:1998;85-120.
76. Gupta R.N., Dziurdzy S.A. Therapeutic monitoring of sertraline. Clin Chem. 40:1994;498-499.
77. Haddad P. Newer antidepressants and the discontinuation syndrome. J Clin Psychiatry. 58(suppl. 7):1997;17-21.
78. Hamelin B.A., Turgeon J., Vallée F., Bélanger P.M., Paquet F., LeBel M. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin Pharmacol Ther. 60:1996;512-521.
79. Härtter S., Wetzel H., Hammes E., Hiemke C. Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients. Psychopharmacology. 110:1993;302-308.
80. Härtter S., Hermes B., Szegedi A., Hiemke C. Automated determination of paroxetine and its main metabolite by column switching and on-line high-performance liquid chromatography. Ther Drug Monit. 16:1994;400-406.
81. Härtter S., Wetzel H., Hammes E., Torkzadeh M., Hiemke C. Non-linear pharmacokinetics of fluvoxamine and gender differences. Ther Drug Monit. 20:1998;446-449. a.
82. Härtter S., Wetzel H., Hammes E., Torkzadeh M., Hiemke C. Serum concentrations of fluvoxamine and clinical effects. A prospective open clinical trial. Pharmacopsychiatry. 31:1998;199-200. b.
83. Harvey A., Lane R. SSRIs and inhibition of the cytochrome P4502D6 isoenzyme. Eur Neuropsychopharmacol. 6(suppl. 3):1996;42.
84. Harvey A.T., Preskorn S.H. Interactions of serotonin reuptake inhibitors with tricyclic antidepressants. Arch Gen Psychiatry. 52:1995;783-784.
85. Harvey A.T., Preskorn S.H. Cytochrome P450 enzymes. Interpretation of their interactions with selective serotonin reuptake inhibitors. Part I J Clin Psychopharmacol. 16:1996;273-285.
86. Harvey A., Preskorn S., Lane R., Wilner K. Sertraline and P4503A/4. Eur Neuropsychopharmacol. 6(suppl. 3):1996;40.
87. Hiemke C., Weigmann H., Härtter S., Dahmen N., Wetzel H., Müller H. Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol. 14:1994;279-281.
88. Hotopf M., Lewis G., Normand C. Are SSRIs a cost-effective alternative to tricyclics? Br J Psychiatry. 168:1996;404-409.
89. Hyttel J. Comparative pharmacology of selective serotonin re-uptake inhibitors (SSRIs). Nord J Psychiatry. 47(suppl. 30):1993;5-12.
90. Hyttel J., Bøgesø K.P., Perregaard J., Sánchez C. The pharmacological effect of citalopram resides in the (S)-(+)-enantiomer. J Neural Transm (Gen Sect). 88:1992;157-160.
91. Hyttel J., Arnt J., Sánchez C. The pharmacology of citalopram. Rev Comtemp Pharmacother. 6:1995;271-285.
92. Jalil P. Toxic reaction following the combined administration of fluoxetine and phenytoin. two case reports J Neurol Neurosurg Psychiatry. 55:1992;412-413.
93. Jefferson J.W. Drug interactions-friend or foe? J Clin Psychiatry. 59(suppl. 4):1998;37-47.
94. Jeppesen U., Gram L.F., Vistisen K., Loft S., Poulsen H.E., Brøsen K. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol. 51:1996;73-78.
95. Jerling M., Lindstrom L., Bondesson U., Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine. evidence from a therapeutic drug monitoring service Ther Drug Monit. 16:1994;368-374.
96. Karlson C.N., Newton J.E., Livingstone R., Jolly J.B., Cooper T.B., Sprigg J., Komorski R.A. Human brain fluoxetine concentrations. J Neuropsychiatry Clin Neurosci. 5:1993;322-329.
97. Kashuba A.D.M., Nafziger A.N., Kearns G.L., Leeder S., Gotschall R., Rocci M.L., Kulawy R.W., Beck D.J., Bertino J.S. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. Clin Pharmacol Ther. 64:1998;257-268.
98. Kasper S., Dötsch M., Kick H., Vieira A., Möller H.J. Plasma concentrations of fluvoxamine and maprotiline in major depression - implications on therapeutic efficacy and side effects. Eur Neuropsychopharmacol. 3:1993;13-21.
99. Kaye C.M., Haddock R.E., Langley P.F., Mellows G., Taker T.C.G., Zussman B.D., Greb W.H. A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiat Scand. 80(suppl. 350):1989;60-75.
100. Kerr B.M., Thummel K.E., Wurden C.J., Klein S.M., Kroetz D.L., Gonzalez F.J., Levy R.H. Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol. 47:1994;1969-1979.
101. Ketter T.A., Post R.M., Worthington K. Principles of clinically important drug interactions with carbamazepine. Part I. J Clin Psychopharmacol. 11:1991;198-203.
102. Kobayashi K., Yamamoto T., Chiba K., Tani M., Ishizaki T., Kuroiwa Y. The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4′-hydroxylase activity in human liver microsomes. Br J Clin Pharmacol. 40:1995;481-485.
103. Kobayashi K., Chiba K., Yagi T., Shimada N., Taniguchi T., Horie T., Tani M., Yamamoto T., Shizaki T., Kuroiwa Y. Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. J Pharmacol Exp Ther. 280:1997;927-933.
104. Koran L.M., Cain J.W., Dominguez R.A., Rush J.A., Thiemann S. Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder? Am J Psychiatry. 153:1996;1450-1454.
105. Kragh-Sørensen P., Fredricson-Overø K., Petersen O.L., Jensen K., Parnas W. The kinetics of citalopram. single and multiple dose studies in man Acta Pharmacol Toxicol. 48:1981;53-60.
106. Kuhs H., Schlake H.P., Rolf L.H., Rudolf G.A.E. Relationship between parameters of serotonin transport and antidepressant plasma levels or therapeutic response in depressive patients treated with paroxetine and amitriptyline. Acta Psychiatr Scand. 85:1992;364-369.
107. Kurz D.L., Bergstrom R.F., Goldberg M.J., Cerimele B.J. The effect of sertraline on the pharmacokinetics of desipramine and imipramine. Clin Pharmacol Ther. 62:1997;145-156.
108. Kuss H.-J., Hegerl U. Serum concentrations of paroxetine are influenced by CYP3A. Naunyn Schmiedebergs Arch Pharmacol. 358:1998;R782.
109. Lane R.M. Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. Int Clin Psychopharmacol. 11(suppl. 5):1996;31-61.
110. Lasher T.A., Fleishaker J.C., Steenwyk R.C., Antal E.J. Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine. Psychopharmacology. 104:1991;323-327.
111. Lecrubier Y. The place of the SSRIs and fluvoxamine in the treatment of patients with depression. Drugs. 43(suppl. 2):1992;1-2.
112. Leinonen E., Koponen H.J., Lepola U. Paroxetine increases serum trimipramine concentration. A report of two cases. Hum Psychopharmacol. 10:1995;345-347.
113. Leinonen E., Lepola U., Koponen H. Substituting carbamazepine with oxacabazepine increases citalopram levels. A report on two cases. Pharmacopsychiatry. 29:1996;156-158.
114. Leo R.J. Movement disorders associated with the selective serotonin reuptake inhibitors. J Clin Psychiatry. 57:1996;449-454.
115. Leonard B., Tollefson G. Focus on SSRIs. broadening the spectrum of clinical use J Clin Psychiatry. 55:1994;459-466.
116. Leonard H.L. New developments in the treatment of obsessive-compulsive disorder. J Clin Psychiat. 58(suppl. 14):1997;39-45.
117. Levine B., Jenkins A.J., Smialek J.E. Distribution of sertraline in postmortem cases. J Anal Toxicol. 18:1994;272-274.
118. Levine M., Bellward G.D. Effect of cimetidine on hepatic cytochrome P450. evidence for formation of a metabolite-intermediate complex Drug Metab Dispos. 23:1995;1407-1411.
119. Levy R.H. Cytochrome P450 isoenzyme and antiepileptic drug interactions. Epilepsia. 36(suppl. 5):1995;S8-S13.
120. Lund J., Lomholt B., Fabricius J., Christensen J.A., Bechgaard E. Paroxetine. pharmacokinetics, tolerance and depletion of blood 5-HT in man Acta Pharmacol Toxicol. 44:1979;289-295.
121. Lundmark J., Thomsen J.S., Fjord-Larsen T., Manniche P.M., Mengel H., Møller-Nielsen E.M., Pauser H., Walinder J. Paroxetine. pharmacokinetic and antidepressant effect in the elderly Acta Psychiatr Scand. 80(suppl. 350):1989;76-80.
122. Milne R.J., Goa K.L. Citalopram. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in depressive illness. Drugs. 41:1991;450-477.
123. Murdoch D., McTavish D. Sertraline. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in depression and obsessive-compulsive disorder. Drugs. 44:1992;604-624.
124. Nelson D.R., Koymans L., Kamataki T., Stegeman J.J., Feyereisen R., Waxman D.J., Waterman M.R., Gotoh O., Coon M.J., Estabrook R.W., Gunsalus I.C., Nebert D.W. P450 superfamily. update on new sequences, gene mapping, accession numbers and nomenclature Pharmacogenetics. 6:1996;1-2.
125. Nemeroff C.B., DeVane C.L., Pollock B.G. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry. 153:1996;311-320.
126. Otton S.V., Wu D., Joffe R.T., Cheung S.W., Sellers E.M. Inhibition of fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther. 53:1993;401-409.
127. Overmars H., Scherpenisse P.M., Post L.C. Fluvoxamine maleate. metabolism in man Eur J Drug Metab Pharmacokinet. 8:1983;269-280.
128. Owens M.J., Morgan W.N., Plott S.J., Nemeroff C.B. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther. 283:1997;1305-1322.
129. Øyehaug E., Østensen E.T. High-performance liquid chromatographic determination of citalopram and four of its metabolites in plasma and urine samples from psychiatric patients. J Chromatogr B. 308:1984;199-208.
130. Piccinelli M., Pini S., Bellantuono C., Wilkinson G. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review. Br J Psychiatry. 166:1995;424-443.
131. Pinninti N.R., de Leon J. Interaction of sertraline with clozapine. J Clin Psychophamacol. 17:1997;119-120.
132. Preskorn S.H. Pharmacokinetics of antidepressants. why and how they are relevant to treatment J Clin Psychiatry. 54(suppl.):1993;14-34.
133. Preskorn S.H. Clinical Pharmacology of Selective Serotonin Reuptake Inhibitors. 1996;Professionals Communications, Inc, Caddo. a.
134. Preskorn S.H. Reducing the risk of drug-drug interactions. a goal of rational drug development J Clin Psychiatry. 57(suppl. 1):1996;3-6. b.
135. Preskorn S.H. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. Clin Pharmacokinet. 32(suppl. 1):1997;1-21.
136. Preskorn S.H., Baker B. Fatality associated with combined fluoxetine-amitriptyline therapy. JAMA. 277:1997;1682.
137. Preskorn S.H., Lane R.M. Sertraline 50 mg daily. the optimal dose in the treatment of depression Int J Clin Psychopharmacol. 10:1995;129-141.
138. Preskorn S.H., Magnus R. Inhibition of hepatic P-450 isoenzymes by serotonin selective reuptake inhibitors. in vitro and in vivo findings and their implications for patient care Psychopharmacol Bull. 30:1994;251-259.
139. Preskorn S.H., Alderman J., Chung M., Harrison W., Messig M., Harris S. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol. 14:1994;90-98.
140. Preskorn S.H., Alderman J.A., Greenblatt D.J., Horst D. Sertraline does not inhibit cytochrome P450 (CYP) 3A-mediated drug metabolism in vivo. Biol Psychiatry. 42:1997;45S.
141. Price J.S., Waller P.C., Wood S.M., McKay A.V. A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmacol. 42:1996;757-763.
142. Priskorn M., Larsen F., Segonzac A., Moulin M. Pharmacokinetic interaction study of citalopram and cimetidine in healthy subjects. Eur J Clin Pharmacol. 52:1997;241-242.
143. Rapeport W.G., Muirhead D.C., Williams S.A., Cross M., Wesnes K. Absence of effect of sertraline on the pharmacokinetics and pharmacodynamics of phenytoin. J Clin Psychiatry. 57(suppl. 1):1996;24-28. a.
144. Rapeport W.G., Williams S.A., Muirhead D.C., Dewland P.M., Tanner T., Wesnes K. Absence of a sertraline-mediated effect of the pharmacokinetics and pharmacodynamics of carbamazepine. J Clin Psychiatry. 57(suppl. 1):1996;20-23. b.
145. Rasmussen B.B., Mäenpää J., Pelkonen O., Loft S., Poulsen H.E., Lykkesfeldt J., Brøsen K. Selective serotonin reuptake inhibitor and theophylline metabolism in human liver microsomes. potent inhibition by fluvoxamine Br J Clin Pharmacol. 39:1995;151-159.
146. Redmond A.M., Harkin A., Kelly J.P., Leonard B.E. Effects of acute and chronic antidepressant administration on phencyclidine (PCP) induced locomotor hyperactivity. Eur Neuropsychopharmacol. 9:1999;165-170.
147. Redmond G. Mood disorders in the female patient. Int J Fertil Womens Med. 42:1997;67-72.
148. Renshaw P.F., Guimaraes A.R., Fava M., Rosenbaum J.F., Pearlman J.D., Flood J.G., Puopolo P.R., Clancy K., Gonzalez R.G. Accumulation of fluoxetine and norfluoxetine in human brain during therapeutic administration. Am J Psychiatry. 149:1992;1592-1594.
149. Richelson E. Pharmacology of antidepressants - characteristics of the ideal drug. Mayo Clin Proc. 69:1994;1069-1081.
150. Rickels K., Schweizer E. Clinical overview of serotonin reuptake inhibitors. J Clin Psychiatry. 51(suppl. B):1990;9-12.
151. Ring B.J., Binkley S.N., Roskos L., Wrighton S.A. Effect of fluoxetine, norfluoxetine, sertraline and desmethylsertraline on human CYP3A catalyzed 1′ hydroxy midazolam formation in vitro. J Pharmacol Exp Ther. 275:1995;1131-1135.
152. Rochat B., Amey M., Baumann P. Analysis of enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography. Ther Drug Monit. 17:1995;273-279. a.
153. Rochat B., Amey M., van Gelderen H., Testa B., Baumann P. Determination of the enantiomers of citalopram, its demethylated and propionic acid metabolites in human plasma by chiral HPLC. Chirality. 7:1995;389-395. b.
154. Rochat B., Amey M., Gillet M., Meyer U.A., Baumann P. Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics. 7:1997;1-10.
155. Ronfeld R.A., Tremaine L.M., Wilner K.D. Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Clin Pharmacokinet. 32(suppl. 1):1997;22-30.
156. Rosenstein D.L., Takeshita J., Nelson J.C. Fluoxetine-induced elevation and prolongation of tricyclic levels in overdose. Am J Psychiatry. 148:1991;807.
157. Rudorfer M.V., Potter W.Z. The role of metabolites of antidepressants in the treatment of depression. CNS Drugs. 7:1997;273-312.
158. Schmider J., Greenblatt D.J., von Moltke L.L., Karsov D., Shader R.I. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro. studies of phenytoin p-hydroxylation Br J Clin Pharmacol. 44:1997;495-498.
159. Seifritz E., Holsboer-Trachsler E., Hemmeter U., Eap C.B., Baumann P. Increased trimipramine plasma levels during fluvoxamine comedication. Eur Neuropsychopharmacol. 4:1994;15-20.
160. Shader R.I., Greenblatt D.J., von Moltke L.L. Fluoxetine inhibition of phenytoin metabolism. J Clin Psychopharmacol. 14:1994;375-376.
161. Shader R.I., von Moltke L.L., Schmider J., Harmatz J.S., Greenblatt D.J. The clinician and drug interactions - an update. J Clin Psychopharmacol. 16:1996;197-201.
162. Shen W.W. The metabolism of psychoactive drugs. a review of enzymatic biotransformation and inhibition Biol Psychiatry. 41:1997;814-826.
163. Silver H., Nassar A. Fluvoxamine improves negative symptoms in treated chronic schizophrenia. an add-on double-blind, placebo-controlled study Biol Psychiatry. 31:1992;698-704.
164. Silver H., Shmugliakov N. Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia. evidence for a specific serotonergic effect from a double-blind study J Clin Psychopharmacol. 18:1998;208-211.
165. Silver H., Kaplan A., Jahjah N. Fluvoxamine augmentation for clozapine-resistant schizophrenia. Am J Psychiatry. 152:1995;1098.
166. Sindrup S.H., Brøsen K., Gram L.F. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine. nonlinearity and relation to the sparteine oxidation polymorphism Clin Pharmacol Ther. 51:1992;288-295. a.
167. Sindrup S.H., Brøsen K., Gram L.F., Hallas J., Skjelbo E., Allen A., Allen G.D., Cooper S.M., Mellows G., Tasker T.C.G., Zussman B.D. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther. 51:1992;278-287. b.
168. Sindrup S.H., Brøsen K., Hansen M.G., Aaes-Jørgensen T., Overø K.F., Gram L.F. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit. 15:1993;11-17.
169. Solai L.K., Mulsant B.H., Pollock B.G., Sweet R.A., Rosen J., Yu K., Reynolds C.F. Effect of sertraline on plasma nortriptyline levels in depressed elderly. J Clin Psychiatry. 58:1997;440-443.
170. Spigset O. Adverse reactions of selective serotonin reuptake inhibitors - Reports from a spontaneous reporting system. Drug Saf. 20:1999;277-287.
171. Spigset O., Carleborg L., Hedenmalm K., Dahlqvist R. Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. Clin Pharmacol Ther. 58:1995;399-403.
172. Spigset O., Granberg K., Hägg S., Norström A., Dahlqvist R. Relationship between fluvoxamine pharmacokinetics and CYP2D6/CP2C19 phenotype polymorphism. Eur J Clin Pharmacol. 52:1997;129-133. a.
173. Spigset O.P., Granberg K., Hägg S., Söderström E., Carleborg I., Dahlqvist R. Non-linear fluvoxamine disposition and relation to some CYP activities. Eur J Clin Pharmacol. 52(suppl.):1997;A172. b.
174. Spigset O., Granberg K., Hägg S., Söderström E., Dahlqvist R. Non-linear fluvoxamine disposition. Br J Clin Pharmacol. 45:1998;257-263.
175. Spina E., Avenoso A., Facciola G., Fabrazzo M., Monteleone P., Maj M., Perucca E., Caputi A.P. Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia. Int Clin Psychopharmacol. 13:1998;141-145.
176. Sproule B.A., Otton S.V., Cheung S.W., Zhong X.H., Romach M.K., Sellers E.M. CYP2D6 inhibition in patients treated with sertraline. J Clin Psychopharmacol. 17:1997;102-106.
177. Stanford S.C. Prozac. panacea or puzzle? Trends Pharmacol Sci. 17:1996;150-154.
178. Stevens J.C., Wrighton S.A. Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450. J Pharmacol Exp Ther. 266:1993;964-971.
179. Stock A.J., Kofoed L. Therapeutic interchange of fluoxetine and sertraline. experience in the clinical setting Am J Hosp Pharm. 51:1994;2279-2281.
180. 19F magnetic resonance spectroscopy investigation in vivo of acute and steady-state brain fluvoxamine levels in obsessive-compulsive disorder. Am J Psychiatry. 154:1997;516-522.
181. Suckow R.F., Roose S.P., Cooper T.B. Effect of fluoxetine on plasma desipramine and 2-hydroxydesipramine. Biol Psychiatry. 31:1992;200-204.
182. Syvalahti E.K., Taiminen T., Saarijarvi S., Lehto H., Niemi H., Ahola V., Dahl M.D., Salokangas R.K. Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients. J Int Med Res. 25:1997;24-32.
183. Szegedi A., Wiesner J., Hiemke C. Improved efficacy and fewer side effects under clozapine treatment after addition of fluvoxamine. J Clin Psychopharmacol. 15:1995;141-143.
184. Szegedi A., Wetzel H., Leal M., Härtter S., Hiemke C. Combination treatment with clomipramine and fluvoxamine. drug monitoring, safety and tolerability data J Clin Psychiatry. 57:1996;257-264.
185. Szegedi A., Wetzel H., Angersbach D., Philipp M., Benkert O. Response to treatment in minor and major depression. results of a double-blind comparative study with paroxetine and maprotiline J Affect Disord. 45:1997;167-178.
186. Tasker T.C.G., Kaye C.M., Zussman B.D., Link C.G.G. Paroxetine plasma levels. lack of correlation with efficacy or adverse events Acta Psychiat Scand. 80(suppl. 350):1989;152-155.
187. Taylor D. Pharmacokinetic interactions involving clozapine. Br J Psychiatry. 171:1997;109-112.
188. Vandel S., Bertschy G., Bonin B., Nezelof S., Francois T.H., Vandel B., Sechter D., Bouzard P. Tricyclic antidepressant plasma levels after fluoxetine
189. van den Berg S.J. Comparing SSRIs. from chemistry to clinical choice Hum Psychopharmacol. 10:1995;S199-S209.
190. van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet. 24:1993;203-220.
191. van Harten J. Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet. 29(suppl. 1):1995;1-9.
192. van Harten J., Duchier J., Devissaguet J.P., van Bemmel P., de Vries M.H., Rghoebar M. Pharmacokinetics of fluvoxamine maleate in patients with liver cirrhosis after single-dose oral administration. Clin Pharmacokinet. 24:1993;177-182.
193. van Harten J., Lönnebo A., Grahnén A. Pharmacokinetics of fluvoxamine after intravenous and oral administration. Neuropsychopharmacology. 10:1994;104S.
194. von Moltke L.L., Greenblatt D.J., Court M.H., Duan S.X., Harmatz J.S., Shader R.I. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine. comparison with other selective serotonin reuptake inhibitor antidepressants J Clin Psychopharmacol. 15:1995;125-131.
195. von Moltke L.L., Greenblatt D.J., Duan S.X., Schmider J., Wright C.E., Harmatz J.S., Shader R.I. Human cytochromes mediating N-demethylation of fluoxetine in vitro. Psychopharmacology. 132:1997;402-407.
196. Walczak D.D., Apter J.T., Halikas J.A., Borison R.L., Carman J.S., Post G.L., Patrick R., Cohn J.B., Cunningham L.A., Rittberg B., Preskorn S.H., Kang J.S., Wilcox C.S. The oral dose-effect relationship for fluvoxamine. a fixed-dose comparison against placebo in depressed outpatients Ann Clin Psychiatry. 8:1996;139-151.
197. Warrington S.J., Ronfeld R.A., Wilner K.D., Lazar J.D. Human pharmacokinetics of sertraline. Clin Neuropharmacol. 15(suppl. 1):1992;54. P-.
198. Wetzel H., Anghelescu I., Szegedi A., Wiesner J., Weigmann H., Härtter S., Hiemke C. Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors. differential effects of fluvoxamine and paroxetine in a prospective study J Clin Psychopharmacol. 18:1998;2-9.
199. Wilkinson T.J., Bgg E.J., Winter A.C., Sainsbury R. Incidence and risk factors for hyponatraemia following treatment with fluoxetine or paroxetine in elderly people. Br J Clin Pharmacol. 47:1999;211-217.
200. Wilner K.D., Henry E.B., Tremaine L.M., Lazar J.D., Gunn K., McEwan J., Moreland T. Effect of sertraline on the pharmacokinetics of oral hypoglycemic agents in healthy volunteers. Clin Neuropharmacol. 15(suppl. 1):1992;54. P-.
201. Wilner K.D., Baris B.A., Foulds G.H., Anziano R.J., Berl T., Ziegler M.G. Multiple dose pharmacokinetics of sertraline in subjects with varying degrees of renal impairment. Eur Neuropsychopharmacol. 6(suppl. 3):1996;41. a.
202. Wilner K.D., Everson G., Foulds G.H., Hansen R.A., Shrestra R., McKinley C., McClain C.J. Multiple dose pharmacokinetics of sertraline in subjects with varying degrees of hepatic impairment. Eur Neuropsychopharmacol. 6(suppl. 3):1996;40. b.
203. Wong D.T., Bymaster F.P., Horng J.S., Molloy B.B. A new selective inhibitor for uptake of serotonin into synaptosomes of rat brain. 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine J Pharmacol Exp Ther. 193:1975;804-811.
204. Xu Z.H., Xie H.G., Zhoou H.H. In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine. Br J Clin Pharmacol. 42:1996;518-521.
205. Ziegler M.G., Wilner K.D. Sertraline does not alter the β-adrenergic blocking activity of atenolol in healthy male volunteers. J Clin Psychiatry. 57(suppl. 1):1996;12-15.